Weekly NIH Funding Opportunities and Notices for December 20, 2019

Policy Notices

- NIH Operates Under a Continuing Resolution
  (NOT-OD-20-046)
  Office of the Director, NIH

General Notices

- Notice of Intent to Publish a Funding Opportunity Announcement for the Laboratory Flexible Funding Model (LFFM) (U18) Clinical Trial Not Allowed
  (NOT-FD-20-004)
  Food and Drug Administration

- NHLBI Division of Blood Diseases and Resources Announces Contact Information for Potential Training and/or Career Development Award Applicants
  (NOT-HL-19-730)
  National Heart, Lung, and Blood Institute

- Notice of Frequently Asked Questions for RFA-HL-20-014 “Rare Disease Cohorts in Heart, Lung, Blood and Sleep Disorders (UG3/UH3 Clinical Trial Not Allowed)”
  (NOT-HL-19-736)
  National Heart, Lung, and Blood Institute

- Announcing the Interagency Collaborative Animal Research Education (ICARE) 2020 Workshop Schedule and Open Registration
  (NOT-OD-20-045)
  National Institutes of Health

- Learning from the Transfer of HIV Interventions from Low- and Middle-Income Countries (LMICs) to the United States: Informing the Plan for America to End the HIV Epidemic
  (NOT-TW-19-008)
  John E. Fogarty International Center
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Allergy and Infectious Diseases
  National Institute of Mental Health
  National Institute on Minority Health and Health Disparities
  National Institute of Nursing Research
  Office of Behavioral and Social Sciences Research

Notice of Changes to Funding Opportunities
• Notice of Participation of the National Institute on Aging (NIA) in PA-18-705 "SBIR Technology Transfer (R43/R44 Clinical Trial Not Allowed)"
  (NOT-AG-20-010)
  National Institute on Aging

• Notice of Clarification of Funding Restriction Information in RFA-AI-19-068, Immune Tolerance Network (Clinical Trial Required UM1)
  (NOT-AI-20-018)
  National Institute of Allergy and Infectious Diseases

• Notice of Change to PAR-19-064, "Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional)"
  (NOT-DA-20-028)
  National Institute on Drug Abuse

• Notice to Extend the Expiration Date of PAR-18-291: Transition to Independent Environmental Health Research (TIEHR) Career Award (K01 Clinical Trial Not Allowed)
  (NOT-ES-20-006)
  National Institute of Environmental Health Sciences

• Notice to Extend the Expiration Date of PAR-18-261: Transition to Independent Environmental Health Research (TIEHR) Career Award (K01 Clinical Trial Required)
  (NOT-ES-20-008)
  National Institute of Environmental Health Sciences

• Notice of Correction to application submission information for NOT-HL-19-724 "Notice of Special Interest (NOSI): Availability of Administrative and Revision Supplements to Expand Vaping Research and Understand EVALI"
  (NOT-HL-19-740)
  National Heart, Lung, and Blood Institute

• Notice of NHLBI Participation in PAR-19-307, "Mechanisms of Mycobacterial-Induced Immunity in HIV-Infected and/or Uninfected Individuals to Inform Innovative Tuberculosis Vaccine Design (R01 Clinical Trial Not Allowed)"
  (NOT-HL-19-745)
  National Heart, Lung, and Blood Institute

• Notice of NLM Participation in PAR-19-343 "Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00 - Independent Clinical Trial Not Allowed)"
  (NOT-LM-20-002)
  National Library of Medicine

• Notice to Extend the Expiration Date for PA-18-141 "Mechanisms, Models, Measurement, & Management in Pain Research (R01 Clinical Trial Optional)"
  (NOT-NS-20-021)
  National Institute of Neurological Disorders and Stroke
  National Center for Complementary and Integrative Health
  National Cancer Institute
  National Institute on Aging
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute of Dental and Craniofacial Research
  National Institute of Diabetes and Digestive and Kidney Diseases
National Institute on Minority Health and Health Disparities
National Institute of Nursing Research

- **Notice to Extend the Expiration Date for PA-18-159 "Mechanisms, Models, Measurement, & Management in Pain Research (R21 Clinical Trial Optional)"
  (NOT-NS-20-022)
  National Institute of Neurological Disorders and Stroke
  National Center for Complementary and Integrative Health
  National Cancer Institute
  National Institute on Aging
  *Eunice Kennedy Shriver* National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute of Dental and Craniofacial Research
  National Institute on Minority Health and Health Disparities
  National Institute of Nursing Research

- **Notice of correction to PA-18-817 "Administrative Supplements for Research on Dietary Supplements"
  (NOT-OD-20-052)
  National Institutes of Health
  John E. Fogarty International Center
  National Center for Complementary and Integrative Health
  National Cancer Institute
  National Eye Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Allergy and Infectious Diseases
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  National Institute of Biomedical Imaging and Bioengineering
  *Eunice Kennedy Shriver* National Institute of Child Health and Human Development
  National Institute on Deafness and Other Communication Disorders
  National Institute of Dental and Craniofacial Research
  National Institute of Environmental Health Sciences
  Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs

- **Notice of Change to Award Budget and Removal of Prior Approval Requirement for PAR-19-099, Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative Innovation Award (U01 Clinical Trial Optional)
  (NOT-TR-20-004)
  National Center for Advancing Translational Sciences

**Requests for Proposal**

- **Broad Agency Announcement (BAA): NHP MHC and KIR Allele Discovery and Typing Technology Development, BAA-NIAID-DAIT-75N93019R00020
  (NOT-AI-20-022)
  National Institute of Allergy and Infectious Diseases

**Notices of Special Interest**

- **Notice of Special Interest (NOSI): Advancing Development of Rapid Point-of-Care Hepatitis C Virus Diagnostics**
Notice of Special Interest (NOSI): Development of Nucleic Acid-based Vaccines Against Seasonal and/or Pandemic Influenza  
(NOT-AI-20-017)  
National Institute of Allergy and Infectious Diseases

Notice of Special Interest: Administrative Supplements to Cancer Center Support Grants to Support Collaborations with the Experimental Therapeutics Clinical Trials Network (ETCTN) through the Early Drug Development Opportunity Program (EDDOP)  
(NOT-CA-20-017)  
National Cancer Institute

Notice of Special Interest: Alzheimers-focused Administrative Supplements for NIH/NCI Grants that are not focused on Alzheimers Disease  
(NOT-CA-20-019)  
National Cancer Institute

Notice of Special Interest (NOSI): Addressing Health Disparities in NIDDK Diseases  
(NOT-DK-20-003)  
National Institute of Diabetes and Digestive and Kidney Diseases

Notice of Special Interest (NOSI): Technological Innovations for Advancing Clinical SPECT Imaging  
(NOT-EB-19-022)  
National Institute of Biomedical Imaging and Bioengineering

Notice of Special Interest (NOSI): Development of Functional Assay Sites to Evaluate Candidate -Omis Variants Associated with Heart, Lung, Blood, or Sleep Disease  
(NOT-HL-19-731)  
National Heart, Lung, and Blood Institute

Notice of Special Interest (NOSI): Development of Animal Models of Down Syndrome and Related Biological Materials as Part of the INCLUDE (INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndrome) Project  
(NOT-OD-20-017)  
National Institutes of Health  
National Eye Institute  
National Institute on Aging  
National Institute on Deafness and Other Communication Disorders  
National Institute of Neurological Disorders and Stroke  
Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs

Notice of Special Interest (NOSI): Administrative Supplements to NCATS CTSA Program KL2 Institutional Career Development Awards as part of the INCLUDE (Investigation of Co-occurring Conditions across the Lifespan to Understand Down syndrome) Project  
(NOT-OD-20-022)  
National Institutes of Health  
National Center for Advancing Translational Sciences
Notice of Special Interest (NOSI): Competitive Supplements/Revisions (R01) Available for INCLUDE (Investigation of Co-occurring Conditions across the Lifespan to Understand Down syndromE) Project (Competitive Supplement/Revision Clinical Trial Optional) (NOT-OD-20-023)
National Institutes of Health
National Cancer Institute
National Heart, Lung, and Blood Institute
National Institute on Aging
National Institute of Arthritis and Musculoskeletal and Skin Diseases
Eunice Kennedy Shriver National Institute of Child Health and Human Development
National Institute on Deafness and Other Communication Disorders
National Institute of Dental and Craniofacial Research
National Institute of Environmental Health Sciences
National Institute of Mental Health
National Institute on Minority Health and Health Disparities
National Institute of Neurological Disorders and Stroke

Notice of Special Interest (NOSI): Availability of Administrative Supplements for the INCLUDE (INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE) Project (NOT-OD-20-024)
National Institutes of Health
National Center for Advancing Translational Sciences
National Cancer Institute
National Eye Institute
National Heart, Lung, and Blood Institute
National Institute on Aging
National Institute of Arthritis and Musculoskeletal and Skin Diseases
Eunice Kennedy Shriver National Institute of Child Health and Human Development
National Institute on Deafness and Other Communication Disorders
National Institute of Dental and Craniofacial Research
National Institute of Environmental Health Sciences
National Institute of General Medical Sciences
National Institute of Neurological Disorders and Stroke
National Institute of Nursing Research
Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs

Notice of Special Interest (NOSI): NIH Research Project Grants on Down Syndrome (R01) for the INCLUDE (INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE) Project (NOT-OD-20-025)
National Institutes of Health
National Eye Institute
National Heart, Lung, and Blood Institute
National Institute on Aging
National Institute of Allergy and Infectious Diseases
National Institute of Arthritis and Musculoskeletal and Skin Diseases
Eunice Kennedy Shriver National Institute of Child Health and Human Development
National Institute on Deafness and Other Communication Disorders
National Institute of Dental and Craniofacial Research
National Institute of Environmental Health Sciences
National Institute of Mental Health
Notice of Special Interest (NOSI): Availability of Administrative Supplements to Accelerate Dissemination of Emerging Glycoscience Tools through Collaborations Between Developers and Early Adopters  
(NOT-RM-20-003)  
Office of Strategic Coordination (Common Fund)

Funding Opportunities

- **Secondary Analysis of Existing Datasets in Heart, Lung, and Blood Diseases and Sleep Disorders (R21 Clinical Trial Not Allowed)**  
  (PAR-20-078)  
  National Heart, Lung, and Blood Institute  

- **Mechanisms of Rejuvenation and Age-Acceleration in Heterochronic Blood Exchange (R01 Clinical Trial Not Allowed)**  
  (RFA-AG-21-002)  
  National Institute on Aging  
  Application Receipt Date(s): June 17, 2020

- **Glial Plasticity in the Aging Brain (R01 Clinical Trial Not Allowed)**  
  (RFA-AG-21-010)  
  National Institute on Aging  
  Application Receipt Date(s): June 17, 2020

- **Novel Therapeutics Directed to Intracellular HIV Targets (R21 Clinical Trial Not Allowed)**  
  (RFA-AI-19-072)  
  National Institute of Allergy and Infectious Diseases  
  Application Receipt Date(s): Only accepting applications for the AIDS Application Due Date listed below.

- **Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (R01 Clinical Trial Optional)**  
  (RFA-CA-20-021)  
  National Cancer Institute  
  Application Receipt Date(s): February 21, 2020; May 28, 2020; September 29, 2020

- **Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U01 Clinical Trial Optional)**  
  (RFA-CA-20-022)  
  National Cancer Institute  
  Application Receipt Date(s): February 21, 2020; May 28, 2020; September 29, 2020

- **Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U54 Clinical Trial Optional)**  
  (RFA-CA-20-023)  
  National Cancer Institute  
  Application Receipt Date(s): February 21, 2020; May 28, 2020; September 29, 2020 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the
listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

- **Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P01 Clinical Trial Optional)**
  (RFA-CA-20-024)
  National Cancer Institute
  Application Receipt Date(s): February 21, 2020; May 28, 2020; September 29, 2020
  All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

- **Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P50 Clinical Trial Optional)**
  (RFA-CA-20-025)
  National Cancer Institute
  Application Receipt Date(s): February 21, 2020; May 28, 2020; September 29, 2020
  All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

- **Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U2C Clinical Trial Optional)**
  (RFA-CA-20-026)
  National Cancer Institute
  Application Receipt Date(s): September 29, 2020

- **Physiologically-based pharmacokinetic/pharmacodynamic model extrapolation to human from rabbit for ophthalmic drug products (U01) Clinical Trials Not Allowed**
  (RFA-FD-20-018)
  Food and Drug Administration
  Application Receipt Date(s): February 27, 2020

- **Bioequivalence of Topical Products: Elucidating Fundamental Principles of Dermal Pharmacokinetics for Microdialysis or Microperfusion Techniques (U01) Clinical Trials Not Allowed**
  (RFA-FD-20-019)
  Food and Drug Administration
  Application Receipt Date(s): February 27, 2020

- **Developmental Mechanisms of Human Structural Birth Defects (P01 Clinical Trial Not Allowed)**
  (RFA-HD-21-013)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  Application Receipt Date(s): March 31, 2020
  All applicants are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.

- **Improving Management of Opioids and Opioid Use Disorder (OUD) in Older Adults (R18)**
  (RFA-HS-20-001)
Agency for Healthcare Research and Quality
Application Receipt Date(s): February 23, 2020

- **Novel Imaging Approaches for detection of Persistent HIV and Neuroimmune dysfunction associated with HIV In the Central Nervous System (CNS) (R01 Clinical Trial Optional)**
  (RFA-MH-20-330)
  National Institute of Mental Health
  National Institute of Neurological Disorders and Stroke
  Application Receipt Date(s): Only accepting applications for the AIDS Application Due Date(s) listed below.

- **Novel Imaging Approaches for detection of Persistent HIV and Neuroimmune dysfunction associated with HIV In the Central Nervous System (CNS) (R21 Clinical Trial Not Allowed)**
  (RFA-MH-20-331)
  National Institute of Mental Health
  Application Receipt Date(s): Only accepting applications for the AIDS Application Due Date(s) listed below.

- **Limited Competition: 4DN Organizational Hub (U01 Clinical Trial Not Allowed)**
  (RFA-RM-20-007)
  Office of Strategic Coordination (Common Fund)
  Application Receipt Date(s): March 17, 2020 No late applications will be accepted for this Funding Opportunity Announcement

- **Limited Competition 4DN Data Coordination and Integration Center (U01 Clinical Trial Not Allowed)**
  (RFA-RM-20-008)
  Office of Strategic Coordination (Common Fund)
  Application Receipt Date(s): March 17, 2020 No late applications will be accepted for this Funding Opportunity Announcement

NIH Funding Opportunities now available in RSS (Really Simple News Syndication) format - see [https://grants.nih.gov/grants/guide/rss_info.htm](https://grants.nih.gov/grants/guide/rss_info.htm) for details.

To UnSubscribe from the NIH Guide Weekly TOC LISTSERV, follow the instructions at [https://grants.nih.gov/grants/guide/listserv.htm](https://grants.nih.gov/grants/guide/listserv.htm)